Factor XIIIa supports microvascular endothelial cell adhesion and inhibits capillary tube formation in fibrin

Blood

Volumn 95, Issue 8, 2000, Pages 2586-2592

  Dallabrida, Susan M ^b   Falls, Lisa A ^b   Farrell, David H ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13A; FIBRIN; INTEGRIN; MAGNESIUM; MANGANESE; MONOCLONAL ANTIBODY; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ANGIOGENESIS; ARTICLE; CAPILLARY; CELL ADHESION; DOSE RESPONSE; ENDOTHELIUM CELL; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MICROVASCULATURE; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

EID: 0034655578     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.8.2586     Document Type: Article

References (54)

1. Duckert F. Documentation of the plasma factor XIII deficiency in man. Ann NY Acad Sci. 1972; 202:190.
2. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol. 1999;237:97.
3. Bailey K, Bettelheim FR, Lorand L, Middlebrook WR. Action of thrombin in the clotting of fibrinogen. Nature. 1951;167:233.
4. McKee PA, Rogers LA, Marier E, Hill RL. The subunit polypeptides of human fibrinogen. Arch Biochem Biophys. 1966;116:271.
5. Francis CW, Marder VJ, Martin SE. Demonstration of a large molecular weight variant of the gamma chain of normal human plasma fibrinogen. J Biol Chem. 1980;255:5599.
6. Wollenstein-Todel C, Mosesson MW. Human plasma fibrinogen heterogeneity: evidence for an extended carboxyl-terminal sequence in a normal γ chain variant (γ′). Proc Natl Acad Sci U S A. 1980;77:5069.
7. Finlayson JS, Suchinsky RT, Dayton AL. Effects of long-term storage on human serum albumin: I. Chromatographic and ultracentrifugal aspects. J Clin Invest. 1960;39:1837.
8. Mosesson MW, Finlayson JS, Umfleet RA. Human fibrinogen heterogeneities. III. Identification of γ chain variants. J Biol Chem. 1972;247:5223.
9. Chung DW, Davie EW. γ and γ′ chains of human fibrinogen are produced by alternative mRNA processing. Biochemistry. 1984;23:4232,
10. Fornace AJ Jr, Cummings DE, Comeau CM, Kant JA, Crabtree GR. Structure of the human γ-fiorinogen gene: alternate mRNA splicing near the 3′ end of the gene produces γA and γB forms of γ-fibrinogen. J Biol Chem. 1984;259:12,826.
11. Wolfenstein-Todel C, Mosesson MW. Carboxy-terminal amino acid sequence of a human fibrinogen γ-chain variant (γ′). Biochemistry. 1981;20: 6146.
12. Farrell DH, Mulvihill ER, Huang S, Chung DW, Davie EW. Recombinant human fibrinogen and sulfation of the γ chain. Biochemistry. 1991;30: 9414.
13. Farrell DH, Thiagarajan P. Chung DW, Davie EW. Role of fibrinogen a and γ chain sites in platelet aggregation. Proc Natl Acad Sci USA. 1992;89: 10,729.
14. Lawrence SO, Wright TW, Francis CW, Fay PJ, Haidaris PJ. Purification and functional characterization of homodimeric γB-γB fibrinogen from rat plasma. Blood. 1993;82:2406.
15. Farrell DH, Thiagarajan P. Binding of recombinant fibrinogen mutants to platelets. J Biol Chem. 1994;269:226.
16. Siebenlist KR, Meh DA, Mosesson MW. Plasma factor XIII binds specifically to fibrinogen molecules containing γ′ chains. Biochemistry. 1996; 35:10,448.
17. Falls LA, Farrell DH. Resistance of γA/γ′ fibrin clots to fibrinolysis. J Biol Chem. 1997;272: 14,251.
18. Schwartz ML, Pizzo SV, Hill RL, McKee PA. Human factor XIII from plasma and platelets: molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem. 1973;248:1395.
19. Chung SI, Lewis MS, Folk JE. Relationships of the catalytic properties of human plasma and platelet transglutaminases (activated blood coagulation factor XIII) to their subunit structure. J Biol Chem. 1974;249:940.
20. Credo RB, Curtis CG, Lorand L. α-chain domain of fibrinogen controls generation of fibrinoligase (coagulation factor XIIIa): calcium ion regulatory aspects. Biochemistry. 1981;20:3770.
21. Pisano JJ, Bronzert TJ, Peyton MP, Finlayson JS. ∈-(γ-glutamyl)lysine cross-links: determination in fibrin from normal and factor XIII-deficient individuals. Ann NY Acad Sci. 1972;202:98.
22. Kreager JA, Devine DV, Greenberg CS. Cytofluorometric identification of plasmin-sensitive factor XIIIa binding to platelets. Thromb Haemost. 1988; 60:88.
23. Barry ELR, Mosher DF. Binding and degradation of blood coagulation factor XIIIa by cultured fibroblasts. J Biol Chem. 1990;265:9302.
24. Ueki S, Takagi J, Saito Y. Dual functions of transglutaminase in novel cell adhesion. J Cell Sci. 1996;109:2727.
25. Greenberg CS, Shuman MA. Specific binding of blood coagulation factor XIIIa to thrombin-stimulated platelets. J Biol Chem. 1984;259:14,721.
26. Cox AD, Devine DV. Factor XIIIa binding to activated platelets is mediated through activation of glycoprotein IIb-IIIa. Blood. 1994;83:1006.
27. Cheresh DA. Death to a blood vessel, death to a tumor. Nature Med. 1998;4:395.
28. 3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest. 1999; 103:229.
29. v integrins. Cell. 1998;95:507.
30. 3-specific humanized mAb. Proc Natl Acad Sci U S A. 1998; 95:6037.
31. Cheresh DA. Human endothelial cells synthesize and express an arg-gly-asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci U S A. 1987;84:6471.
32. Dejana E, Languino LR, Colella S, et al. The localization of a platelet GpIIb-IIIa-related protein in endothelial cell adhesion structures. Blood. 1988; 71:566.
33. Slaughter TF, Achyuthan KE, Lai TS, Greenberg CS. A microtiter plate transglutaminase assay utilizing 5-(biotinamido)pentylamine as substrate. Anal Biochem. 1992;205:166.
34. Schwartz ML, Pizzo SV, Hill RL, McKee PA. The effect of fibrin-stabilizing factor on the subunit structure of human fibrin. J Clin Invest. 1971;50: 1506.
35. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680.
36. Ades EW, Candal FJ, Swerlick RA, et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol. 1992;99:683.
37. Stupack DG, Stewart S, Carter WG, Wayner A, Wilkins JA. B lymphocyte fibronectin receptors: expression and utilization. Scand J Immunol. 1991;34:761.
38. Sanchez-Madrid F, Nagy JA, Bobbins E, Simon P, Springer TA. A human leukocyte differentiation antigen with distinct alpha-subunits and a common beta-subunit: the lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/Mac-1), and the p150, 95 molecule. J Exp Med. 1983;158:1785.
39. 3-integrins. J Biol Chem. 1994;269:960.
40. Nehls V, Drenckhahn D. A novel, microcarrier-based in vitro assay for rapid and reliable quantification of three-dimensional cell migration and angiogenesis. Microvasc Res. 1995;50:311.
41. Xu Y, Swerlick RA, Sepp N, Bosse D, Ades EW, Lawley TJ. Characterization of expression and modulation of cell adhesion molecules on an immortalized human dermal microvascular endothelial cell line (HMEC-1). J Invest Dermatol. 1994; 102:833.
42. Bar-Shavit R, Sabbah V, Lampugnani MG, et al. An arg-gly-asp sequence within thrombin promotes endothelial cell adhesion. J Cell Biol. 1991; 112:335.
43. Ruoslahti E. Cell-to-cell contact and extracellular matrix. Curr Opin Cell Biol. 1997;9:605.
44. Thiagarajan P, Rippon AJ, Farrell DH. Alternative adhesion sites in human fibrinogen for vascular endothelial cells. Biochemistry. 1996;35:4169.
45. Devine DV, Andestad G, Nugent D, Carter CJ. Platelet-associated factor XIII as a marker of platelet activation in patients with peripheral vascular disease. Arterioscler Thromb. 1993;13:857.
46. Brooks PC. Cell adhesion molecules in angiogenesis. Cancer Metastasis Rev. 1996;15:187.
47. Hynes RO, Bader BL. Targeted mutations in integrins and their ligands: their implications for vascular biology. Thromb Haemost. 1997;78:83.
48. Ruoslahti E. Integrins as signaling molecules and targets for tumor therapy. Kidney Int. 1997;51: 1413.
49. Ichinose A, Davie EW. Characterization of the gene for the a subunit of human factor XIII (plasma transglutaminase), a blood coagulation factor. Proc Natl Acad Sci U S A. 1988;85:5829.
50. 1. J Biol Chem. 1990;265:4020.
51. Yee VC, Pedersen LC, Bishop PD, Stenkamp RE, Teller DC. Structural evidence that the activation peptide is not released upon thrombin cleavage of factor XIII. Thromb Res. 1995;78:389.
52. 2-antiplasmin to fibrin. Thromb Haemost. 1992; 68:315.
53. O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses MA. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem. 1999;274:29,568.
54. O'Reilly MS, Pine-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science. 1999;285:1926.